The EORTC 18071 phase III trial
evaluated ipilimumab as adjuvant therapy for patients with high risk stage III melanoma.
Not exact matches
Current clinical trials include combination of intrahepatic embolization and a radiosensitizer in patients with uveal melanoma and liver - only metastases, a phase I trial that
evaluates a combination therapy of BCG with
ipilimumab in Stage III / IV melanoma, and several landmark international trials including a phase II trial that
evaluates combination immunotherapy with nivolumab &
ipilimumab.
In the largest analysis of PD - 1 blockade in mucosal melanoma to date, patients treated in clinical studies with either nivolumab monotherapy or nivolumab combined with
ipilimumab were
evaluated in a pooled analysis.
Our multicenter retrospective analysis
evaluated 33 patients with advanced mucosal melanoma who received
ipilimumab, the majority of whom had been pretreated with at least one prior line of therapy.
Primary analysis of a phase 1b multicenter trial to
evaluate safety and efficacy of talimogene laherparepvec (T - VEC) and
ipilimumab (ipi) in previously untreated, unresected stage IIIB - IV melanoma.